drugset / Trial / NCT00297089

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

NCT00297089

Phase 1/2 Completed 165 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the efficacy of ABT-751 when administered in combination with standard pemetrexed in subjects with advanced or metastatic NSCLC. The Phase 1 portion of the study is complete and the study is currently enrolling subjects in Phase 2.

Timeline

Start
2006-11
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator ABT-751 Other / unclassified 200 mg Oral
Comparator Pemetrexed Small molecule 500 mg/m2 Intravenous